BLU-5937 is a Small Molecule owned by BELLUS Health, and is involved in 8 clinical trials, of which 5 were completed, and 3 are ongoing.

BLU-5937 (NEO-5937) is P2X3 receptor antagonist. P2X3 ligand-gated ion channel may transduce ATP-evoked nociceptor activation. The drug candidate binds to the P2X3 receptor and blocks ATP-mediated hypersensitivity in primary afferents, thereby reducing visceral pain and improving the symptoms of PBS/IC.

The revenue for BLU-5937 is expected to reach a total of $607m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the BLU-5937 NPV Report.

BLU-5937 was originated by AstraZeneca and is currently owned by BELLUS Health.

BLU-5937 Overview

BLU-5937 (NEO-5937) is under development for the treatment of chronic refractory cough and and other cough hypersensitization-related disorders. The drug candidate is a benzoimidazole derivative, formulated as a tablet and is administered through oral route. The drug candidate targets P2X purinoceptor 3 (P2X3) receptor. It was also under development for interstitial cystitis (PBS/IC), osteoarthritis pain, visceral pain and chronic pruritus associated with atopic dermatitis.

BELLUS Health Overview

BELLUS Health is a clinical-stage biopharmaceutical company that focuses on developing novel therapeutics for treating patients with chronic cough and hypersensitization-related disorders. The company’s lead product, BLU-593 (formerly NEO5937) is a potent, orally bio-available, highly selective small-molecule antagonist of the P2X3 receptor which is being developed for treating refractory chronic cough, and chronic pruritus associated with atopic dermatitis. It has license agreement and collaborations with NEOMED institute for the development and commercialization of BLU-593. The company operates in Canada and the US through its subsidiaries. BELLUS Health is headquartered in Laval, Quebec, Canada.

The operating loss of the company was US$73.3 million in FY2021, compared to an operating loss of US$32.9 million in FY2020. The net loss of the company was US$71.2 million in FY2021, compared to a net loss of US$31.8 million in FY2020.

Quick View – BLU-5937

Report Segments
  • Innovator
Drug Name
  • BLU-5937
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Dermatology
  • Respiratory
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.